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Rotavirus remains the most common cause of severe,
dehydrating diarrhea among children worldwide. Several
rotavirus vaccines are under development. Decisions about
new vaccine introduction will require reliable data on dis-
ease impact. The Asian Rotavirus Surveillance Network,
begun in 2000 to facilitate collection of these data, is a
regional collaboration of 36 hospitals in nine countries or
areas that conduct surveillance for rotavirus hospitalizations
using a uniform World Health Organization protocol. We
summarize the Network’s organization and experience from
August 2001 through July 2002. During this period, 45% of
acute diarrheal hospitalizations among children 0–5 years
were attributable to rotavirus, higher than previous esti-
mates. Rotavirus was detected in all sites year-round. This
network is a novel, regional approach to surveillance for
vaccine-preventable diseases. Such a network should pro-
vide increased visibility and advocacy, enable more efficient
data collection, facilitate training, and serve as the paradigm
for rotavirus surveillance activities in other regions.
I
n recent years, several international agencies, including
the World Health Organization (WHO), the Global
Alliance for Vaccines and Immunization (GAVI), and the
Children’s Vaccine Program at the Program for
Appropriate Technology in Health (PATH), have identified
the accelerated development and introduction of a
rotavirus vaccine to be among their highest priorities. This
decision was made based on the high incidence of
rotavirus, the most common cause of severe diarrhea in
children worldwide. An estimated 440,000 children die of
rotavirus each year (1), and in developing countries, 5% of
all deaths in children <5 years of age are due to rotavirus.
Furthermore, rotavirus is responsible for 25% to 50% of all
hospitalizations of children for diarrhea in both industrial-
ized and developing countries (2). After 2 decades of vac-
cine development and testing, the principles for making
safe and effective, live oral vaccines have been firmly
established, and several new candidate vaccines are cur-
rently in the late stage of development (3). Given the
importance of rotavirus, GAVI has initiated the
Accelerated Development and Introduction Program to
expedite the development, evaluation, and introduction of
rotavirus vaccines into the poorest countries with the goal
of preventing most rotavirus deaths and hospitalizations
within the next decade.
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rotavirus, physicians and policymakers in most developing
countries, where rotavirus causes the most fatalities and
cases of severe disease and where new vaccines could have
their greatest value, know little about rotavirus in their
location. While these physicians and policymakers may
appreciate that diarrhea is the first or second leading cause
of death in children <5 years of age, the diagnosis of
rotavirus is rarely, if ever, made at the local level.
Moreover, acute diarrhea is treated with rehydration,
regardless of the cause, so a diagnosis is not required, and
no specific means of preventing rotavirus currently exists.
Consequently, rotavirus is not often viewed as a priority
and is incorrectly considered a disease that can be prevent-
ed by improvements in water and sanitation. If a vaccina-
tion program against rotavirus is to be successful, local
leaders must understand the disease, which might include
initiating surveillance of rotavirus, assessing the full inci-
dence of rotavirus disease, and appreciating the impact that
a new vaccine might have if added to the existing program
of childhood immunizations.
In an effort to create regional awareness of the inci-
dence of rotavirus disease and let countries assess the
potential value of rotavirus vaccines currently being devel-
oped, we established the Asian Rotavirus Surveillance
Network (ARSN), the first regional collaboration of its
kind, as a pilot program for epidemiologic surveillance and
advocacy. As members of this network, participating coun-
tries in the region conduct sentinel hospital surveillance to
monitor rates of rotavirus among children hospitalized for
diarrhea in several major hospitals by using a common
protocol and comparable diagnostic test. The goal is to
understand the epidemiology and impact of rotavirus diar-
rhea in the region, to educate physicians and health leaders
about the importance of this problem, and let them assess
the potential public health value of introducing vaccines.
The same surveillance system could ultimately be used to
monitor the impact of a vaccination effort.
Although many of the participating sites had begun sur-
veillance up to 6 months earlier, we report preliminary data
for the first year of the network, in which all but one coun-
try had completed a full year of surveillance, August
2001–July 2002. Data from Korea are not included
because investigators in that country began surveillance in
June 2002 and did not have a full year’s data to report. We
report data from >16,000 children hospitalized for diarrhea
and tested for rotavirus in 33 hospitals in eight Asian coun-
tries or regions. Our results document the rates of rotavirus
in the region, identify features in the epidemiology of the
disease that might effect future immunization efforts, and
underscore the value of regional surveillance networks to
collect data with the same protocol and to test specimens
with comparable diagnostic assays.
ARSN 
ARSN is a collaboration of investigators from medical
centers and public health agencies in nine Asian countries
or regions. The goal of the group is to define the epidemi-
ology and rates of rotavirus disease in Asia and to use these
data to make informed decisions regarding the possible
future use of rotavirus vaccines. ARSN was formed in
2000 in response to a WHO report that called for expedit-
ed rotavirus vaccine evaluation and introduction in Asia
(4). WHO commissioned a generic protocol for sentinel
hospital surveillance of rotavirus that would allow investi-
gators in many countries to assess, in a simple, economi-
cal, and timely fashion, the epidemiology and disease
prevalence of rotavirus (5). This protocol provides the
minimum requirements for hospital-based surveillance,
with attention to collecting and testing fecal samples, and
includes an appendix to identify the catchment population
for the hospital, suggestions to assess the prevalence of
fatal rotavirus disease, and a discussion of the methods to
characterize rotavirus strains.
Goals and Organizational Structure
The goals of ARSN are to use the generic protocol as a
basis to: 1) define the epidemiology and strain distribution
of rotavirus in participating countries, 2) estimate the costs
associated with rotavirus and its prevalence in these set-
tings, 3) create a surveillance system that can monitor the
effectiveness of a vaccine program once introduced, 4)
serve as a basis to conduct enhanced surveillance with spe-
cial studies (e.g., cost-benefit or death rate studies) to
inform decision makers considering a new vaccine pro-
gram, and 5) describe trends in rotavirus activity and strain
distribution over a large geographic region over time.
ARSN consists of 13 collaborating institutions in nine
countries or regions that conduct hospital-based surveil-
lance to monitor the rate of rotavirus infection among chil-
dren hospitalized with diarrhea. The network is supported
by five international donor groups, and coordination is
provided by the Centers for Disease Control and
Prevention (CDC) (Table 1). The lead groups in each coun-
try are responsible for establishing a hospital surveillance
network, ensuring the timely collection of data, creating
the laboratory capacity to test fecal specimens for rotavirus
and to characterize strains identified, performing the
analysis, and writing the report. A summary of all surveil-
lance data is submitted electronically to CDC each month,
and CDC prepares and distributes a quarterly report to all
participants.
The basic structure for surveillance of children hospi-
talized for diarrhea is described in the Generic Protocol
available from the WHO website (5). In brief, it provides
that all children <59 months of age admitted to a partici-
pating hospital with physician-diagnosed acute diarrhea of
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form data are collected from the medical records by using
a standard questionnaire that includes date of admission,
age and sex of the patient, symptoms of illness, and out-
come. A fresh fecal specimen is obtained from each child,
placed in a clean container, and stored at 4°C until tested
for rotavirus with an enzyme immunoassay (EIA), either
Rotaclone (Meridian Diagnostics, Inc., Cincinnati, OH) or
DAKOPATTS (DAKO Diagnostics Ltd., Glostrup,
Denmark), or by polyacrylamide gel electrophoresis
(PAGE). Testing is conducted at the participating hospital
laboratory or at the coordinating institution in the country.
Each site tracks the proportion of total diarrheal admis-
sions tested for rotavirus as an indicator of the sensitivity
of the system to monitor disease. A subset of samples
found to be positive for rotavirus is tested for G and P
types by using reverse transcriptase–polymerase chain
reaction (RT-PCR) according to published methods (6).
Samples are selected for strain characterization on the
basis of representativeness in terms of seasonal and age
distribution and their quality. The generic protocol was
pilot tested in Vietnam, and the encouraging results of this
survey led to some simplifications and improvements in
the study methods (7). Individual country proposals were
reviewed and approved by ethical review boards in mem-
ber institutions.
Progress during the First Year
Surveillance began in Hong Kong in December 2000,
and by August 2002, 36 hospitals in 26 cities or towns in
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Table 1. Member institutions and participating hospitals of the Asian Rotavirus Surveillance Network 
Sites  Lead institution(s)  Participating hospitals 
China  Institute of Virology, Chinese Center for Disease 
Control, Ministry of Health, Beijing 
Southeast University, Nanjing 
International Vaccine Institute 
Beijing Friendship Hospital 
Changchun Children’s Hospital 
Lulong County Hospital 
Lulong Maternal and Child Health Hospital 
Kunming Hospital 
Ma-An-Shan Steel Trust Hospital 
Suzhou University-Affiliated Children’s Hospital 
Hong Kong  Chinese University of Hong Kong,  
New Territories 
Prince of Wales Hospital 
Queen Elizabeth Hospital 
Tuen Mun Hospital 
Pamela Youde Nethersole Eastern Hospital 
Indonesia  Gadjah Mada University, Yogyakarta  Dr. Sardjito Teaching Hospital, Yogyakarta 
Wirosaban District Hospital, Yogyakarta 
Purworejo Hospital, Purworejo 
Korea  Chonbuk National University 
International Vaccine Institute, Seoul 
ChungEub Asan Foundation Medical Center, Chonbuk 
National University Hospital 
Chonju Presbyterian Medical Center 
Malaysia  Institute of Pediatrics, Kuala Lumpur University,  
Kuala Lumpur 
Kuala Lumpur Hospital, Kuala Lumpur 
Kuching Hospital, Kuching, Sarawak 
Myanmar  Department of Medical Research,  
Ministry of Health 
Yangon Children’s Hospital, Yangon 
Taiwan  Taiwan Center for Disease Control, Taipei  National Taiwan University Hospital, Taipei 
Veteran General Hospital, Taipei 
Veteran General Hospital, Taichung 
Veteran General Hospital, Kaohsiung 
Thailand  Ministry of Public Health, Bangkok  Nongkhai Hospital 
Maesod Hospital 
Prapokklao Hospital 
Ramathibodi Hospital 
Hadyai Hospital 
Srakaew Hospital 
Vietnam  National Institute of Hygiene and Epidemiology, Hanoi 
POLIOVAC, Hanoi 
Pasteur Institute, Ho Chi Minh City 
St. Paul’s Hospital, Hanoi 
Swedish Children’s Hospital, Hanoi 
Children’s Hospital, Hai Phong 
General Hospital, Khan Hoa 
General Pediatric Hospital #1, Ho Chi Minh City 
General Pediatric Hospital #2, Ho Chi Minh City nine Asian countries or regions were actively participating
and routinely reporting their results (Table 1).
Collaborators from Korea joined the network, with 3 hos-
pitals reporting in June 2002. Of the 36 hospitals conduct-
ing surveillance, 19 (53%) are in large urban settings, 14
(39%) are in smaller cities, and 3 (8%) are rural hospitals.
Seventeen (47%) are tertiary-care hospitals.
As of July 2002, seven of nine regions had collected 1
full year of data, and two collaborating countries (Korea
and Myanmar) had collected data for <1 full year. From
August 2001 through July 2002, a total of 11,498 stool
samples were obtained from 16,173 patients, which repre-
sented more than 71% of all children admitted to partici-
pating hospitals with acute gastroenteritis (Table 2). Each
month, participating hospitals collected fecal specimens
from 679 to 1,556 children <5 years of age. Overall,
rotavirus was detected in 45% (n = 5,124) of stools tested,
with a range among hospitals of 18% to 67%. When only
the sites that contributed 12 full months of data during this
period were surveyed (to account for seasonal peaks of
rotavirus disease), rotavirus was still detected in 44% of
children tested. Rotavirus was detected year-round in all
sites; however, wintertime peaks (November to March)
were evident in the most northern areas (China, Taiwan,
Hong Kong), while seasonal peaks were not as clearly
defined in more southern sites, with tropical climates
(Vietnam, Thailand, Malaysia) (Figure 1 and 2).
By mid-2002, five sites had begun strain characteriza-
tion: China, Malaysia, Vietnam, Hong Kong, and Taiwan.
CDC sponsored ARSN investigators from Indonesia,
Taiwan, Vietnam, and Korea to train in Atlanta, and as a
result, these sites have initiated genotyping of specimens
from surveillance in these countries as of mid-2003.
Finally, arrangements have been made for training a scien-
tist from Myanmar in Hong Kong and will begin soon.
CDC provided technical expertise, reagents, and protocols
for some of the laboratory work and will provide assis-
tance in resolving nontypeable strains. 
Discussion
ARSN was organized to allow for the timely and eco-
nomic collection of quality data on the effect of rotavirus
infections in Asia, to collect these data efficiently, and to
facilitate use of the data to inform decision makers about
possibly introducing rotavirus vaccines. During the first
year of the collaboration, ARSN produced valuable data
that also yielded some surprises, and it has contributed to
local and regional training, capacity building, advocacy,
and development of the infrastructure for surveillance in
member sites. Preliminary data from ARSN reaffirm that
rotavirus remains a major cause of severe gastroenteritis
among infants and young children. Moreover, rotavirus
predominates in all sites, whether urban or rural, north or
south, industrialized or developing, regardless of a coun-
try’s gross national product. In addition, unlike rotavirus
hospitalizations in the United States (8,9) and Europe (10),
those in the ARSN settings occurred year-round, although
seasonal peaks in disease were observed in the northern-
most sites, areas with more temperate climates. These find-
ings are similar to those found in the summary from the
African data of Cunliffe et al. (2). The finding that
rotavirus disease occurs with high frequency in settings
with a variety of sanitation conditions reinforces the
hypothesis that vaccines, not improved hygiene and water
quality, are the best strategy to prevent this disease (3).
The preliminary finding of such high rates of rotavirus
in sites throughout the region among children hospitalized
for diarrhea confirms pilot studies in Vietnam that identi-
fied rotavirus in >50% of patients hospitalized with diar-
rhea (7). These high rates have implications for our global
estimates of the prevalence of rotavirus disease. The most
recent estimates of the global prevalence of rotavirus dis-
ease were determined on the basis of a literature review of
studies conducted in the late 1980s and 1990s that estimat-
ed the percentage of rotavirus detected among children
hospitalized for diarrhea (1). In this study, the authors esti-
mated that from 20% (for low-income countries) to 34%
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Table 2. Rates of rotavirus detection in Asian Rotavirus Surveillance Network sites, August 2001–July 2002 
Sites  Start of surveillance 
No. stool samples 
tested 
% (no.) one rotavirus-
positive sample 
Range of % rotavirus-positive  samples 
among participating hospitals 
China  Aug 2001  2,079  44 (910)  24–65 
Korea
a  Jun 2002  N/A  N/A  N/A 
Taiwan  Apr 2001  1,532  49 (744)  43–53 
Hong Kong  Dec 2000  2,986  28 (829)  18–35 
Vietnam  Feb 2001  1,570  59 (921)  47–67 
Myanmar
b  Dec 2001  388  53 (204)  53
c 
Thailand  Feb 2001  992  44 (436)  38–49 
Malaysia  Feb 2001  1,374  57 (778)  52–59 
Indonesia  Aug 2001  577  52 (302)  47–57 
Overall    11,498  45 (5,124)  18–67 
aData from Korea absent due to start of surveillance in June 2002. 
bPartial year of data. 
cSingle hospital in Myanmar participating in surveillance. (for high-income countries) of hospitalizations for children
>5 years were due to rotavirus infection. Data collected by
the ARSN sites indicate higher rates of rotavirus illness in
hospitalized children than used in previous models that
have estimated rotavirus-associated disease and death
globally. Indeed, the findings of the ARSN sites presented
here are generally higher than those in previous studies in
ARSN member countries that used similar methods (Table
3), but agree with recent data  from studies in South
America and Africa (31,32), and to recent rates from other
investigators in Asia (33). One hypothesis for this differ-
ence is that improvements in sanitation and hygiene have
reduced the number of diarrheal cases caused by bacteria
and parasites, but less so the number due to rotavirus,
because of differences in modes of transmission. As a
result, the proportional fraction of diarrheal disease due to
rotavirus rather than other causes increases as populations
gain better access to clean water and sanitation. Among
ARSN sites, rates of rotavirus detection in industrialized
Hong Kong have changed little over the past decade, while
countries with developing economies generally have found
estimates higher than those from studies conducted in the
1970s and 1980s. Reports of bacterial enteric disease sur-
veillance from some relatively high-income countries have
demonstrated decreasing rates of disease (34–36); howev-
er, few data document trends of bacterial and parasitic
enteric infections in industrialized countries. In addition,
indirect support of the hypothesis comes from diarrheal
death rates in Mexico during the 1990s (37) and the United
States in the 1980s (38). In both settings, summer and win-
ter peaks of diarrheal death rates have, over time, been
replaced by single wintertime peaks. In Mexico, the
decrease in summertime diarrheal death rates was associ-
ated with improvements in water supply. In both countries,
wintertime rotavirus peaks in deaths have declined steadi-
ly over time but remain comparatively high. 
An alternative explanation for the high detection rates
could be the strict adherence to standard stool sample col-
lection and handling procedures or the use of more sensi-
tive tests compared to previous studies. Because
rotaviruses are relatively stable in whole stool samples
and because the studies chosen for comparison of current
data all used comparable enzyme-linked immunosorbent
assays, we think that the methods used by our network
probably had little impact on detection rates. The princi-
pal advantage of the use of the standardized surveillance
protocols remains the ease with which it allows for initia-
tion of surveillance and enables collection of comparable
data from very diverse settings. Finally, the reasons that
data from Hong Kong generally reflected lower rates of
disease than other sites remain unclear and deserve addi-
tional study. These preliminary data highlight the need to
collect data in countries considering rotavirus vaccine
introduction.
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Figure 1. Seasonality of rotavirus (RV) in member countries of the Asian Rotavirus Surveillance Network. A, China; B, Vietnam; C,
Taiwan; D, Thailand.During this study, surveillance for rotavirus was initiat-
ed and sustained with ease, even in very large hospitals.
The Generic Protocol for Rotavirus Disease Burden
Estimation from WHO provides simple guidelines on
organizing surveillance and interpreting the data. This pro-
tocol formed the basis of this network. Since diagnosis of
rotavirus diarrhea is relatively easy compared with other
vaccine-preventable diseases, ARSN was able to establish
rotavirus testing by using EIA or PAGE at each site. Data
collection was simplified by use of a one-page standard
data-collection form contained in the Generic Protocol as a
template for each site’s form and by creation of a premade
data entry form and analysis program in EpiInfo (CDC,
Atlanta, GA) (available by request from the authors).
The use of regional networks to document rotavirus
strain distribution within a region will add to the global
understanding of prevalent strains and help in making
informed decisions on vaccine composition. Although,
strain characterization data from ARSN members during
the 12 months of surveillance reported here were not yet
complete, knowledge of circulating strains may also help
guide local decisions on vaccine introduction and will be
important in postlicensure assessment of vaccine effective-
ness. Since the leading vaccine candidates employ differ-
ent strategies, some monovalent human or animal strains
and some polyvalent human-animal reassortants, conduct-
ing field trials of new vaccines in settings that include
diverse, naturally occurring strains will be important.
Surveillance networks, such as the ARSN, facilitate data
collection for vaccine trials and act as a resource for labo-
ratory scientists.
Regional, cooperative surveillance networks create
training and infrastructure, building opportunities for
members and creating a mechanism to introduce new tech-
nologies. While detecting rotavirus is easy and rapid, char-
acterizing strains requires a higher level of technical skill.
ARSN work has been supported by the WHO
Collaborating Center for Rotavirus and Other Viral Agents
of Gastroenteritis to conduct strain typing for sites without
the capacity to do so and to facilitate training and quality
control for laboratories interested in performing these
tests. When ARSN was formed, four member sites
(Thailand National Institute of Health, Chinese University
of Hong Kong, National Institute of Hygiene and
Epidemiology in Vietnam, and China’s Institute of Viral
Disease Control and Prevention) had performed rotavirus
strain typing. By the end of the first year, strains had been
characterized by using RT-PCR by eight of the sites, and
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Figure 2. Seasonality of rotavirus (RV) in member countries of the Asian Rotavirus Surveillance Network. A, Hong Kong; B, Malaysia; C,
Myanmar; D, Indonesia.scientists from Myanmar were receiving training in this
method. In addition, ARSN has provided a platform for
professional development for epidemiologists and health-
care personnel involved in the study.
Future Directions 
The final product from ARSN will be data that coun-
tries in the region can use to assess their need for a
rotavirus vaccine and, where needed, to facilitate their
introduction into immunization programs. The work of
ARSN can serve as a paradigm of additional regional
activities to promote the understanding and appreciation of
the disease prevalence and costs associated with rotavirus
in the region. Other regional rotavirus surveillance net-
works are also established in Africa and are being estab-
lished in Latin America and will help accelerate decisions
on vaccine introduction in those regions. The next step is
to link these data to advocacy efforts. The value of any sur-
veillance data is in its application or its ability to inform
decisions. The new initiative of GAVI, the Accelerated
Development and Introduction Program for Rotavirus
Vaccines (available from: www.vaccinealliance.org), will
serve as a pathway to transform data from networks like
ARSN into action.
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